文献速递前列腺癌

隔日或每周一次:前列腺SABR的2期PATRIOT试验长期肿瘤学结局

Every Other Day or Once a Week: Long-term Oncological Outcomes in the Phase 2 PATRIOT Trial of Prostate Stereotactic Ablative Body Radiotherapy.
PubMed 文献 · Eur Urol Oncol · 2025-04-26

PATRIOT多中心2期试验将有利风险局限性前列腺癌男性随机分为隔日(EOD)或每周一次(QW)五分割前列腺SABR。中位随访91个月,两组生化失败、无转移生存、前列腺癌特异性生存和总生存均无显著差异。

要点

  • EOD与QW组8年生化失败累积发生率分别为5.5%与9.6%(p=0.2)。
  • EOD与QW组8年无转移生存率分别为100%与95.9%(p=0.08)。
  • EOD与QW组8年总生存率分别为96.0%与85.4%(p=0.3)。

核心结论

  • 五分割前列腺SABR的EOD与QW方案在长期肿瘤学结局上无显著差异。

研究设计与样本

  • PATRIOT多中心2期试验的事后分析,有利风险局限性前列腺癌男性随机接受EOD(n=77)或QW(n=75)五分割前列腺SABR。

主要发现

  • 中位随访91个月,EOD组与QW组8年生化失败累积发生率分别为5.5%与9.6%(p=0.2)。
  • EOD组与QW组8年无转移生存率分别为100%与95.9%(p=0.08)。
  • EOD组与QW组8年前列腺癌特异性生存率分别为100%与97.2%(p=0.2)。
  • EOD组与QW组8年总生存率分别为96.0%与85.4%(p=0.3)。

临床怎么用

  • 对于有利风险局限性前列腺癌,五分割SABR选择EOD或QW方案对长期肿瘤学结局无显著影响。

局限性

  • 样本量小,研究效能为检测急性肠道生活质量差异而设计。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: The PATRIOT multicentre phase 2 trial showed that prolongation of overall treatment time (OTT) for prostate stereotactic ablative body radiotherapy (SABR) was associated with better acute bowel and urinary quality of life. However, the impact on long-term cancer outcomes is unclear. METHODS: Men with favourable-risk localised prostate cancer in the PATRIOT trial were randomised to five-fraction prostate SABR every other day (EOD; n = 77) or once weekly (QW; n = 75).The cancer outcomes evaluated in this post hoc analyses were biochemical failure (BF), metastasis-free survival (MFS), prostate cancer-specific survival (PCSS), and overall survival (OS). KEY FINDINGS AND LIMITATIONS: Median follow-up was 91 mo. The 8-yr cumulative incidence rates for BF were 5.5% in the EOD arm versus 9.6% the QW arm (p = 0.2). The 8-yr probability rates were 100% versus 95.9% for MFS (p = 0.08), 100% versus 97.2% for PCSS (p = 0.2), and 96.0% versus 85.4% for OS (p = 0.3) for the EOD versus QW arms, respectively. The study is limited by the small sample size (powered to detect significant differences in acute bowel quality of life). CONCLUSIONS: This study suggests no significant differences in long-term cancer outcomes between EOD and QW schedules for five-fraction prostate SABR. This trial is registered on ClinicalTrials.gov as NCT01423474.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Ong WL, Quon H, Ong A, et al. Every Other Day or Once a Week: Long-term Oncological Outcomes in the Phase 2 PATRIOT Trial of Prostate Stereotactic Ablative Body Radiotherapy. Eur Urol Oncol. 2025. PMID: 40288917. doi:10.1016/j.euo.2025.03.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。